Clinical data | |
---|---|
Routes of administration | Oral |
ATC code |
|
Legal status | |
Legal status |
|
Identifiers | |
| |
CAS Number |
|
PubChem CID | |
IUPHAR/BPS | |
ChemSpider | |
UNII |
|
KEGG | |
ChEMBL | |
CompTox Dashboard ( EPA) | |
Chemical and physical data | |
Formula | C33H43N3O6 |
Molar mass | 577.722 g·mol−1 |
3D model ( JSmol) | |
| |
| |
(verify) |
Aplaviroc ( INN, codenamed AK602 and GSK-873140) is a CCR5 entry inhibitor that belongs to a class of 2,5-diketopiperazines [1] developed for the treatment of HIV infection. [2] [3] It was developed by GlaxoSmithKline.
In October 2005, all studies of aplaviroc were discontinued due to liver toxicity concerns. [4] [5] Some authors have claimed that evidence of poor efficacy may have contributed to termination of the drug's development; [6] the ASCENT study, one of the discontinued trials, showed aplaviroc to be under-effective in many patients even at high concentrations. [7]
Clinical data | |
---|---|
Routes of administration | Oral |
ATC code |
|
Legal status | |
Legal status |
|
Identifiers | |
| |
CAS Number |
|
PubChem CID | |
IUPHAR/BPS | |
ChemSpider | |
UNII |
|
KEGG | |
ChEMBL | |
CompTox Dashboard ( EPA) | |
Chemical and physical data | |
Formula | C33H43N3O6 |
Molar mass | 577.722 g·mol−1 |
3D model ( JSmol) | |
| |
| |
(verify) |
Aplaviroc ( INN, codenamed AK602 and GSK-873140) is a CCR5 entry inhibitor that belongs to a class of 2,5-diketopiperazines [1] developed for the treatment of HIV infection. [2] [3] It was developed by GlaxoSmithKline.
In October 2005, all studies of aplaviroc were discontinued due to liver toxicity concerns. [4] [5] Some authors have claimed that evidence of poor efficacy may have contributed to termination of the drug's development; [6] the ASCENT study, one of the discontinued trials, showed aplaviroc to be under-effective in many patients even at high concentrations. [7]